Carotid baroreceptor stimulation: A promising approach for the management of resistant hypertension and heart failure

Current Vascular Pharmacology

Volumn 12, Issue 1, 2014, Pages 30-37

  Doumas, M ^a,b   Faselis, C ^b   Kokkinos, P ^b,c   Anyfanti, P ^a   Tsioufis, C ^c,d   Papademetriou, V ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Baroreflex; Carotid baroreceptor stimulation; Heart failure; Heart failure with preserved ejection fraction; Hypertension; Resistant hypertension; Sympathetic nervous system

Indexed keywords

ADRENERGIC SYSTEM; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR THERAPEUTIC DEVICE; CAROTID SINUS PRESSORECEPTOR; CLINICAL TRIAL (TOPIC); DEVICE SAFETY; ELECTROSTIMULATION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MUSCLE SYMPATHETIC NERVE ACTIVITY; NONHUMAN; PARASYMPATHETIC TONE; RESISTANT HYPERTENSION;

BAROREFLEX; CAROTID SINUS; DISEASE MANAGEMENT; DRUG RESISTANCE; ELECTRIC STIMULATION THERAPY; HEART FAILURE; HUMANS; HYPERTENSION; PRESSORECEPTORS; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 84897441248     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990138     Document Type: Article

References (51)

1. Doumas M, Faselis C, Tsioufis C, Papademetriou V. Carotid baroreceptor activation for the treatment of resistant hypertension and heart failure. Curr Hypertens Rep 2012; PMID: 22457242.
2. A Dictionary of Medical Derivations: The Real Meaning of Medical Terms; by William Casselman, Parthenon Publishing Group, Apr 15, 1998.
3. Parry CH. On a case of nervous affection cured by pressure of the carotids with some physiological remarks. Philos Transact Royal Soc 1811; 101: 89-95.
4. Doumas M, Papademetriou V, Douma S, et al. Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens 2010; 2011: 318549.
5. Doumas M, Guo D, Papademetriou V. Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions. Expert Opin Ther Targets 2009; 13: 413-25.
6. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-9.
7. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31: 68-72.
8. Tsioufis C, Kordalis A, Flessas D, et al. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens 2011; 2011:642416.
9. Bristow JD, Honour AJ, Pickering GW, Sleight P, Smyth HS. Diminished baroreflex sensitivity in high blood pressure. Circulation 1969; 39: 48-54.
10. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010; 298: R245-53.
11. Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010; 55: 619-26.
12. Wustmann K, Kucera JP, Scheffers I, et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009; 54: 530-6.
13. Lohmeier TE, Irwin ED, Rossing MA, Serdar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 2004; 43: 306-11.
14. Lohmeier TE, Dwyer TM, Irwin ED, Rossing MA, Kieval RS. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension 2007; 49: 1307-14.
15. Scheffers I, Kroon A, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension. Results of a European Multi-Center Feasibility Study J Am Coll Cardiol 2010; 56: 1254-8.
16. Kroon A, Schmidli J, Scheffers I, et al. Sustained blood pressure reduction by baroreflex activation therapy with a chronically implanted system: 4-year data of Rheos DEBuT-HT study in patients with resistant hypertension. J Hypertens 2010; 28:e441.
17. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension. Results from the double-blind, randomized, placebocontrolled Rheos Pivotal trial. J Am Coll Cardiol 2011; 58: 765-73.
18. Scheffers I, Schmidli J, Kroon AA, et al. Sustained blood pressure reduction by baroreflex hypertension therapy with a chronically implanted system: 2-year data from the Rheos DEBuT-HT study in patients with resistant hypertension. J Hypertens 2008, 26(Suppl 1): S19.
19. van Onzenoort H, Menger F, Neef C, et al. Participation in a clinical trial enhances adherence and persistence to treatment. A retrospective cohort study. Hypertension 2011; 58: 573-8.
20. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity and mortality in hypertension: Results in patients with diastolic blood pressures averaging 115-129 mmHg. JAMA 1967; 202: 116-22.
21. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012; 6: 152-8.
22. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
23. Tordoir JH, Scheffers I, Schmidli J, et al. An implantable carotid sinus baroreflex activating system: surgical technique and shortterm outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg 2007; 33: 414-21.
24. Hoppe UC, Brandt M, Wachter R, et al. Minimally invasive system for baroreceptor activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012; 6:270-6.
25. Bisognano JD, Kaufman CL, Bach DS, Lovett EG, de Leeuw P, DEBuT-HT and Rheos Feasibility Trial Investigators. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol 2011; 57: 1787-8.
26. Wachtell K, Gerdts E, Aurigemma GP, et al. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE study. Blood Press 2010; 19: 169-75.
27. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292: 2343-9.
28. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009; 54: 1084-91.
29. Georgakopoulos D, Wagner D, Cates AW, Irwin E, Lovett EG. Effects of electrical stimulation of the carotid sinus baroreflex using the Rheos device on ventricular-vascular coupling and myocardial efficiency assessed by pressure-volume relations in non vagotomised anesthetized dogs. Conf Proc IEEE Eng Med Biol Soc 2009; 2009: 2025-9.
30. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex hypertension therapy improves cardiac structure and function in resistant hypertension: results from the Pivotal trial of the Rheos system. J Am Coll Cardiol 2011; 57: E491.
31. Croft JB, Giles WH, Pollard RA, Keenan NL, Casper ML, Anda RF. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999; 159: 505-10.
32. Stewart S, MacIntyre K, Capewell S, McMurray JJ. Heart failure and the aging population: an increasing burden in the 21st century? Heart 2003; 89: 49-53.
33. Fu Q, Zhang R, Witkowski S, et al. Persistent sympathetic activation during chronic antihypertensive therapy: a potential mechanism for long term morbidity? Hypertension 2005; 45: 513-21.
34. McCormack PL, Wagstaff AJ. Lacidipine: a review of its use in the management of hypertension. Drugs 2003; 63: 2327-56.
35. La Rovere MT, Pinna GD, Maestri R, et al. Prognostic implications of baroreflex sensitivity in heart failure patients in the betablocking era. J Am Coll Cardiol 2009; 53: 193-9.
36. Sabbah HN, Gupta RC, Imai M, et al. Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodelling in dogs with advanced heart failure. Circ Heart Fail 2011; 4: 65-70.
37. Wang M, Zaca V, Jiang A, et al. Long-term baroreflex activation therapy increases the threshold for the induction of lethal ventricular arrhythmias in dogs with chronic advanced heart failure. Circulation 2008; 118: S721.
38. Zucker I, Hackley J, Cornish K, et al. Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension 2007; 50: 904-10.
39. Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-81.
40. Massie BM, Carson PE, McMurray JJ, et al. I-PRESERVE Investigators Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-67.
41. Bisognano JD, de Leeuw P, Bach DS. Improved functional capacity and cardiovascular structure after baroreflex activation therapy in resistant hypertension patients with symptomatic heart failure: results from European and United States trials of the Rheos system. J Cardiac Fail 2009; 15: S63.
42. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a metaanalysis. J Hypertens 2004; 22: 435-445.
43. Ishikawa J, Carroll DJ, Kuruvilla S, Schwartz JE, Pickering TG. Changes in home versus clinic blood pressure with antihypertensive treatments: a meta-analysis. Hypertension 2008; 52: 856-64.
44. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens 2012; 30: 874-6.
45. Papademetriou V, Doumas M, Faselis C, et al. Carotid baroreceptor stimulation for the treatment of resistant hypertension. Int J Hypertens 2011; 2011: 964394.
46. Chapleau MW, Hajduczok G, Abboud FM. Pulsatile activation of baroreceptors causes central facilitation of baroreflex. Am J Physiol 1989; 256: H1735-41.
47. Doumas M, Douma S. Interventional management of resistant hypertension. Lancet 2009; 373: 1228-30.
48. Doumas M, Douma S. Renal sympathetic denervation: the jury is still out. Lancet 2010; 376: 1878-80.
49. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension. Am J Cardiol 2010; 105: 570-6.
50. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation in hypertension. Curr Opin Nephrol Hypertens 2011; 20: 647-53.
51. Lohmeier TE, Iliescu R, Liu B, Henegar JR, Maric-Bilkan C, Irwin ED. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 2012; 59: 331-8.